Evoke Wealth’s Fulgent Genetics FLGT Stock Holding History

Evoke Wealth’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-21	Closed	-$2K	–	1188
2021 Q1	$2K	Buy	+21	New	+$2.17K	﹤0.01%	1026

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Evoke Wealth's FLGT Position: Q2 2021 in Review

Evoke Wealth sold out of Fulgent Genetics (FLGT) in Q2 2021, closing a stake of 21 shares — an estimated $2K sold.

Evoke Wealth first reported a position in FLGT in Q1 2021 and held it in 1 quarter. The position peaked at $2K in Q1 2021. 254 funds tracked by Wall St. Rank hold FLGT as of Q2 2021.

Evoke Wealth reported no remaining Fulgent Genetics position as of Q2 2021 after selling out during the quarter.
Evoke Wealth sold 21 Fulgent Genetics shares in Q2 2021, an estimated $2K.
Evoke Wealth first reported a position in Fulgent Genetics in Q1 2021 and held it in 1 quarter.
Evoke Wealth's Fulgent Genetics position peaked at $2K in Q1 2021.
254 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2021.

Based on Evoke Wealth's 13F filing for Q2 2021, filed 5 Aug 2021.